⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1897868 | 1.00 | — | — | |
| SCHEMBL8336407 | 1.00 | — | — | |
| SCHEMBL7955778 | 0.86 | — | — | |
| SCHEMBL2399791 | 0.72 | — | — | |
| SCHEMBL7418051 | 0.72 | — | — | |
| SCHEMBL75546 | 0.70 | — | — | |
| SCHEMBL3183061 | 0.70 | — | — | |
| SCHEMBL75545 | 0.70 | — | — | |
| SCHEMBL22567117 | 0.70 | — | — | |
| SCHEMBL8565574 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 319 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4629989-A2 | TREATMENT OR PREVENTION OF DEPRESSIVE DISORDERS THROUGH COMBINATION THERAPY | Freedom Biosciences, Inc. (US) | 2025-10-15 | — | — | EP | claimed |
| US-20240382556-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF ALCOHOL DEPENDENCE | DUKE UNIVERSITY | 2024-11-21 | — | — | US | claimed |
| US-20240350433-A1 | TREATMENT COMPOSITIONS AND METHODS | UNIV YALE (US) | 2024-10-24 | — | — | US | claimed |
| WO-2024123935-A2 | TREATMENT OR PREVENTION OF DEPRESSIVE DISORDERS THROUGH COMBINATION THERAPY | FREEDOM BIOSCIENCES, INC. (US) | 2024-06-13 | — | — | WO | claimed |
| US-20220296558-A1 | COMPOSITIONS FOR IMPROVING BRAIN HEALTH AND MEMORY | CYTOSOLVE, INC. | 2022-09-22 | — | — | US | claimed |
| EP-3958973-A1 | COMPOSITIONS FOR IMPROVING BRAIN HEALTH AND MEMORY | Cytosolve, Inc. (US) | 2022-03-02 | — | — | EP | claimed |
| US-20220031798-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF OPIOID DEPENDENCE AND FOR THE TREATMENT OF PAIN | DUKE UNIVERSITY (US) | 2022-02-03 | — | — | US | claimed |
| WO-2020219975-A1 | COMPOSITIONS FOR IMPROVING BRAIN HEALTH AND MEMORY | CYTOSOLVE, INC. (US) | 2020-10-29 | — | — | WO | claimed |
| WO-2018144551-A2 | COMPOUNDS FOR TREATMENT OR PREVENTION OF DISORDERS OF THE NERVOUS SYSTEM AND SYMPTOMS AND MANIFESTATIONS THEREOF, AND FOR CYTO-PROTECTION AGAINST DISEASES AND AGING OF CELLS, AND SYMPTOMS AND MANIFESTATIONS THEREOF | MANFREDI PAOLO L (US) | 2018-08-09 | — | — | WO | claimed |
| US-20180214395-A1 | Compounds for Treatment or Prevention of Disorders of the Nervous System and Symptoms and Manifestations Thereof, and for Cyto-Protection Against Diseases and Aging of Cells, and Symptoms and Manifestations Thereof | MANFREDI PAOLO L (US) | 2018-08-02 | — | — | US | claimed |
| WO-2000024395-A1 | NEW USE OF GLUTAMATE ANTAGONISTS FOR THE TREATMENT OF CANCER | IKONOMIDOU HRISSANTHI (DE) | 2000-05-04 | — | — | WO | claimed |
| US-6025369-A | N-methyl-D-aspartate (NMDA) receptor blockers for the prevention of atherosclerosis | THE BOARD OF REGENTS OF THE UNIVERSITY NEBRASKA (US) | 2000-02-15 | — | — | US | claimed |
| US-5629336-A | Use of glycine/NMDA receptor ligands for the treatment of drug dependence and withdrawal | MERCK, SHARP & DOHME LTD. (GB) | 1997-05-13 | — | — | US | claimed |
| US-5614509-A | Pharmaceutical agents for preventing the development of tolerance during the treatment with benzodiazepine-receptor-binding active ingredients | SCHERING AKTIENGESELLSCHAFT (DE) | 1997-03-25 | — | — | US | claimed |
| EP-0514023-B1 | Use of glycine/NMDA receptor ligands for the manufacture of a medicament for the treatment of drug dependence and withdrawal | MERCK SHARP & DOHME (GB) | 1996-03-20 | — | — | EP | claimed |
| EP-0318091-B1 | RESOLVED AMINO PYRROLIDINE NEUROPROTECTIVE AGENTS | MERCK SHARP & DOHME LTD. (GB) | 1992-12-09 | — | — | EP | claimed |
| EP-0514023-A1 | Use of glycine/NMDA receptor ligands for the manufacture of a medicament for the treatment of drug dependence and withdrawal | MERCK SHARP & DOHME LTD. (GB) | 1992-11-19 | — | — | EP | claimed |
| US-4863953-A | [3R]-3-amino-1-hydroxy pyrrolidin-2-one and its use as a neuroprotective agent | MERCK & CO., INC. (US) | 1989-09-05 | — | — | US | claimed |
| EP-0318091-A2 | Resolved amino pyrrolidine neuroprotective agents | MERCK SHARP & DOHME LTD. (GB) | 1989-05-31 | — | — | EP | claimed |
| US-4129652-A | CHLORPROMAZINE OR THIORIDAZINE AND 5-ETHYL-5-PHENYL-2-PYRROLIDONE OR 1-HYDROXY-3-AMINO-2-PYRROLIDONE OR SALTS | NELSON RESEARCH & DEVELOPMENT COMPANY (US) | 1978-12-12 | — | — | US | claimed |